



## Press Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Sunao Manabe, Representative Director, President and CEO  
(Code no.: 4568, First Section, Tokyo Stock Exchange)  
Release address inquiries to Junichi Onuma,  
Vice President, Corporate Communications Department  
Telephone: +81-3-6225-1126  
<https://www.daiichisankyo.com>

### **Daiichi Sankyo Enters into Outsourcing Agreement to Manufacture AstraZeneca COVID-19 Vaccine in Japan**

**Tokyo, Japan (February 5, 2021)** – Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) is pleased to announce that it recently entered into an outsourcing agreement with AstraZeneca K.K. (hereinafter, AstraZeneca) to manufacture the AstraZeneca-developed COVID-19 vaccine, AZD1222, in Japan.

In order to play a part in the COVID-19 vaccine manufacturing and supply scheme agreed upon between AstraZeneca and the government of Japan, Daiichi Sankyo will use undiluted solutions provided by AstraZeneca to manufacture COVID-19 vaccines in the country, including vial filling and packaging, in accordance with the outsourcing agreement.

The manufacture of the COVID-19 vaccine, AZD1222, will be undertaken by Daiichi Sankyo Biotech Company, Limited, a subsidiary of Daiichi Sankyo, at a facility dedicated to the Ministry of Health, Labour and Welfare’s “project to establish a system for developing and producing novel influenza virus vaccines.”

As it strives to help restore safety and security in society through the early eradication of COVID-19, Daiichi Sankyo, in addition to ensuring the stable supply of the AstraZeneca COVID-19 vaccine in Japan, will continue to work to advance ongoing research and development of a Nafamostat inhalation formulation (DS-2319) as well as an mRNA vaccine (DS-5670)

## **About Daiichi Sankyo**

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: <https://www.daiichisankyo.com/>